Acceleron Clinical Trials

Clinical Trials

Clinical Trials

At Acceleron, we are dedicated to bringing innovative, life-changing therapies to patients with a wide range of serious and rare diseases. Our scientific leadership and broad platform have enabled us to produce a rich pipeline of important new medicines for rare blood disorders, neuromuscular, and pulmonary diseases.

  • We are developing luspatercept, our lead product candidate, for the treatment of the chronic anemias in myelodysplastic syndromes (MEDALIST Phase 3 trial ongoing and COMMANDS Phase 3 trial planned), beta-thalassemia (BELIEVE Phase 3 trial ongoing), and myelofibrosis (Phase 2 trial ongoing). The goal of these trials is to reduce or eliminate the need for regular red blood cell transfusions. Luspatercept is currently under a global partnership with Celgene.
  • ACE-083 is being studied in two, two-part Phase 2 trials; one trial is being conducted in facioscapulohumeral muscular dystrophy (FSHD) and the other is being conducted in Charcot-Marie-Tooth (CMT) disease.
  • In our pulmonary program, our newest disease focus area, we recently initiated the PULSAR Phase 2 trial in pulmonary arterial hypertension.

With multiple Phase 2 and Phase 3 trials ongoing in 2018, we believe that we are poised to make a meaningful difference in the lives of patients with severe and rare diseases who have few or no therapeutic options.

The clinical trials listed below are Acceleron or partner-sponsored trials that are actively recruiting patients. Each trial in the list contains a link to, where you will find a full description and contact information.

DrugStudy PhaseDiseaseStudy ID
Phase III
Myelodysplastic Syndromes (MDS)
Phase III
LuspaterceptPhase II ExtensionMDSNCT02268383
LuspaterceptPhase II ExtensionBeta-ThalassemiaNCT02268409
LuspaterceptPhase IIBeta-ThalassemiaNCT01749540
LuspaterceptBEYOND Phase IIBeta-ThalassemiaNCT03342404
LuspaterceptPhase IIAnemia in Lower-Risk MDSNCT01749514
LuspaterceptPhase IIMyelofibrosisNCT03194542
SotaterceptPhase IIMyelofibrosisNCT01712308
ACE-083Phase IIFacioscapulohumeral Muscular DystrophyNCT02927080
ACE-083Phase IICharcot-Marie-Tooth DiseaseNCT03124459
SotaterceptPULSAR Phase IIPulmonary Arterial HypertensionNCT03496207
ACE-2494Phase IHealthy Volunteers NCT03478319
Acceleron trials listed as recruiting or active on